Search PubMed⌕ Search

Biomedical subjects

G Senaldi

Publications and source records attributed to G Senaldi.

45 records · Page 3Linked to original sources
PubMed1981

[Evaluation of the methylthymol blue and orthocresolphthalein direct methods of determination of serum calcium].

Two methods for the direct colorimetric determination of serum calcium (BMT and OCFT) have been evaluated and compared with atomic absorption spectrophotometry (AAS). Both colorimetric methods resulted simple to use, but temperature-sensitive: values for the ratio absorbance at 10 degrees C/absorbance at 45 degrees C were 1.6 (BMT) and 1.8 (OCFT). When readings were taken at 37 degrees C good precision was achieved with both methods (between-the-series coefficients of variation were 3.5 divided by 2.2% for OFCT and 1.9 divided by 3.4% for BMT). No interference from bilirubin (up to 180 mumol/l) was observed with both methods; slight positive interference from haemoglobin (1 g/l) was observed only with OCFT method. Results from the two colorimetric methods closely agreed in the range 1.0 divided by 4.5 mmol/l: statistical analysis of comparison data gave BMT = 0.0963 + 0.9521 OCFT, r = 0.9820. From the results of direct comparison with AAS (103 serum specimens, concentration spanning from 1.0 to 4.5 mmol/l) statistical analysis gave: BMT (y)/AAS(x): y = 0.0721 + 1.0226x (r = 0.9678); OCFT(y)AAS(x): y = -0.0208 + 1.0720x (r = 0.9836): it is concluded that both methods show a slight positive bias with respect to AAS.

Bromthymol Blue↗
PubMedDate not supplied

Serum beta 2-microglobulin levels in multiple myeloma and monoclonal gammapathy of undetermined significance: a clinical study of 55 patients.

Previous reports provided clear evidence that serum beta 2-microglobulin (beta 2m) is a marker highly correlated with the total mass of myeloma cells and suggested its use in the follow-up of patients with plasma cell tumors. Serum beta 2m levels were measured in 38 patients with multiple myeloma (MM), in 17 patients with monoclonal gammapathy of undetermined significance (MGUS) and in 32 normal control subjects. While statistically significant differences could be established between controls and both MM and MGUS patients, between patients with MM at stage III and patients with MM at lower stages as well as between patients with MGUS and patients with mostly advanced MM, it was not possible to statistically separate patients with MM at stage I from patients with MM at stage II, patients with untreated MM from patients with treated MM and, finally, patients with MGUS from patients with low cell mass MM. These results substantially confirm the already published data and lead to the conclusion that serum beta 2m determination is a useful test in the clinical management of monoclonal gammapathies, but it does not allow a differential diagnosis between benign and malignant forms of the disease.

Aged↗